Ngoc Nguyen
Research Associate
Expertise:
Since joining EVERSANA as a Research Associate in 2023, Ngoc has been involved in conducting systematic literature reviews, budget impact analyses, cost-effectiveness analyses, and real-world evidence studies.
Ngoc has authored 8 publications and has experience spanning several therapeutic areas, including lung cancer, multiple myeloma, chronic kidney disease, heart failure, diabetes, tuberculosis, and COPD. He has strong experience in using R and VBA programming for data analysis and economic evaluation.
Before joining EVERSANA, Ngoc was a hospital pharmacist at the National Lung Hospital and a Research Assistant at the National Drug Information and Adverse Drug Reactions Monitoring Centre in Vietnam, where he gained substantial first-hand experience in clinical practice and research.
Articles by Ngoc Nguyen
Enhancing Quality of Life in Advanced Breast Cancer: The Role of Palbociclib
Advanced breast cancer often comes with significant physical symptoms, such as pain and fatigue, as well as side effects from treatments. The diagnosis and treatment of advanced breast cancer can lead to anxiety, depression and stress. Improving a patient’s quality of life can help manage these symptoms more effectively, making daily life more bearable. Focusing on quality of life in the face of a challenging diagnosis has become a primary goal of breast cancer therapy, particularly in the advanced setting, where outcomes are often poor. Palbociclib, a first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, received approval from the United States (U.S.) Food and Drug Administration in 2015 for the treatment of […]
Real-World Effectiveness of Treatments Post-CDK4/6i in Treating HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Since the FDA’s approval of palbociclib plus letrozole in 2015, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), in combination with endocrine therapy (ET), have become the standard of care for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced/metastatic breast cancer (HR+/HER2- LABC/mBC) in the first-line (1L) treatment setting. However, there is no clear standard of care for patients after 1L CDK4/6i treatment. Understanding the real-world effectiveness of subsequent therapies may help to identify an unmet need in this patient population. The Value & Evidence team at EVERSANA (Sarah Kane, Belal Howidi, Ngoc Nguyen, Joanna Bielecki and Imtiaz A. Samjoo) synthesized the effectiveness of treatments received in the real-world setting […]